- HOME
- Vol.43 No.11
- CLINICA NEUROL, 43: 802－804, 2003
- Vol.43 No.11 contents
The 44th Annual Meeting of the Japanese Society of Neurology
Symposium 2-4: Critical illness polyneuropathy and myopathy
Masakatsu Motomura, M.D.
First Department of Internal Medicine, Graduate School of Biomedical Sciences, Nagasaki University
Critical Illness Polyneuropathy (CIP) and Myopathy (CIM), either singly or in combination, are a common complication of critical illness. Both disorders may lead to severe weakness and require mechanical ventilation. CIP, as initially described by Bolton et al., in 1984, is a sensorimotor polyneuropathy that is often a compliction of sepsis and multiorgan failure. In Japan, Horinouchi et al., first reported a case in 1994. CIM has been referred to by a number of different terms (acute quadriplegic myopathy, thick filament myopathy, acute necrotizing myopathy of intensive care, rapidly evolving myopathy with myosin-deficiency fibers) in the literature. A variety of serious problems (eg, pneumonia, severe asthma, and lung or liver transplantation) and the concomitant use of high-dose intravenous corticosteroids and nondepolarizing neuromuscular blocking agents predispose to CIM. In Japan, Kawada et al., reported a first case as acute quadriplegic myopathy in 2000. There is no specific treatment for CIP and CIM. Minimizing the use of corticosteroids and nondepolarizing neuromuscular blocking agents in a critical illness setting may prove helpful in preventing the occurrence of these disorders. The prognosis is directly related to the age of the patient and the seriouness of the underlying illness.
(CLINICA NEUROL, 43: 802－804, 2003)
key words: critical illness polyneuropathy (CIP), critical illness myopathy (CIM), systemic inflammatory response syndrome (SIRS), intensive care unit (ICU)
(Received: 16-May-03)
